01:14 , Nov 16, 2018 |  BC Innovations  |  Emerging Company Profile

Virion: Harnessing viral defects

Virion Biotherapeutics Ltd. has capitalized on a naturally occurring viral mutation to develop broad-spectrum antivirals with lower potential for resistance than marketed products. Its lead compound, VH244, is in preclinical development to treat respiratory infections...
20:44 , Feb 10, 2017 |  BC Week In Review  |  Financial News

Atriva Therapeutics completes venture financing

On Feb. 7, influenza play Atriva Therapeutics GmbH (Tübingen, Germany) raised €1.5 million ($1.6 million) in the first close of a planned €3 million ($3.2 million) seed round led by Stichting Participatie Atriva and High-Tech...
08:00 , Dec 21, 2015 |  BioCentury  |  Emerging Company Profile

New purpose in flu

Atriva Therapeutics GmbH is repurposing MEK inhibitors to stop influenza viruses from hijacking host cellular pathways necessary for viral replication. The strategy may provide better efficacy than existing flu therapies by avoiding viral resistance. Roche's...